Parotid gland radiation dose-xerostomia relationships based on actual delivered dose for nasopharyngeal carcinoma

Jingjiao Lou1* | Pu Huang1* | Changsheng Ma2 | Yue Zheng1 | Jinhua Chen2 | Yueqiang Liang2 | Hongsheng Li2 | Yong Yin2 | Danhua Liu1 | Gang Yu1 | Dengwang Li1

1Shandong Province Key Laboratory of Medical Physics and Image Processing Technology, Institute of Biomedical Sciences, School of Physics and Electronics, Shandong Normal University, No.88, Wenhua East Road, Jinan, 250014, China
2Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, No.440, Jiyan Road, Jinan, 250117, China

Abstract
Xerostomia induced by radiotherapy is a common toxicity for head and neck carcinoma patients. In this study, the deformable image registration of planning computed tomography (CT) and weekly cone-beam CT (CBCT) was used to override the Hounsfield unit value of CBCT, and the modified CBCT was introduced to estimate the radiation dose delivered during the course of treatment. Herein, the beams from each patient’s treatment plan were applied to the modified CBCT to construct the weekly delivered dose. Then, weekly doses were summed together to obtain the accumulated dose. A total of 42 parotid glands (PGs) of 21 nasopharyngeal carcinoma patients were analyzed. Doses delivered to the parotid glands significantly increased compared with the planning doses. V20, V30, V40, Dmean, and D50 increased by 11.3%, 28.6%, 44.4%, 9.5%, and 8.4% respectively. Of the 21 patients included in the study, eight developed xerostomia and the remaining 13 did not. Both planning and delivered PG Dmean for all patients exceeded tolerance (26 Gy). Among the 21 patients, the planning dose and delivered dose of Dmean for patients with xerostomia was 30.6 Gy and 33.6 Gy, respectively, for patients without xerostomia, and 26.3 Gy and 28.0 Gy, respectively, for patients without xerostomia. The D50 of the planning and delivered dose for patients was below tolerance (30 Gy). The results demonstrated that the p-value of V20, V30, V40, Dmean, and D50 difference of the delivery dose between patients with xerostomia and patients without xerostomia was less than 0.05. However, for the planning dose, the significant dosimetric difference between the two groups only existed in D50 and Dmean. Xerostomia is closely related to V20, V30, D50, and Dmean.

PACS
87.53.Tf Treatment planning, optimization, tissue response factors, dose-volume analysis

KEY WORDS
cone-beam CT, deformable image registration, nasopharyngeal carcinoma, xerostomia

*These authors contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2018 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
1 | INTRODUCTION

Oral complications induced by radiotherapy are universal in the treatment of head and neck carcinomas (HNC). Xerostomia results from the deleterious effect of radiation, and is the most common persistent oral sequela for HNC patients who receive therapeutic doses.1 It occurs with difficulties in swallowing and speaking, loss of taste, and dental caries, which have a detrimental impact on the quality of life.2 The occurrence of xerostomia is related to several factors such as the radiation dose, the volume of irradiated tissue, and the use of concurrent radiation sensitizing and chemotherapy drugs. Much research has been performed on delivering radiation to normal tissue to spare patients from the development of complications. Intensity-modulated radiation therapy (IMRT) has been considered as the standard therapeutic technique of HNC because of its highly conformal, modulated techniques.3,4 It permits the delivery of a high dose to the target volume and spares the surrounding critical structures. Several studies have noted that IMRT has advantages over three-dimensional conformal radiotherapy in terms of sparing the parotid gland (PG), and it can improve the quality of life for HNC patients.5,6 However, position variations and anatomical changes over the course of treatment limit the benefits of IMRT and lead to a clinically significant dose difference between the initial plan and delivery.

Previous studies have shown that anatomy changes may cause more dose deviations in organs at risk (OARs) than in target volumes.7–10 It is true that changes in anatomy were found among most of the nasopharyngeal carcinoma (NPC) patients.11 Generally, bodyweight loss, primary tumor shrinkage, and PG volume reduction could induce a PG dose change and increase the risk of xerostomia. In order to correct these deviations, adaptive radiotherapy (ART), online re-optimization, or offline replanning is recommended.12,13

Castelli et al. investigated the impact of ART to spare the PG and decrease the risk of xerostomia using weekly computed tomography (CT), and included the PG overdose, the benefit of ART, and anatomical markers related to dose differences between the planning and accumulated dose (with/without replanning).2 Although the time and the optimal number of replanning incidents remain unclear and the strategies of replanning remain uncertain, the benefits of ART have previously been demonstrated.14 However, it is not likely that patients can obtain CBCT scans for every fraction during the entire treatment, and not every patient will benefit from ART. Thus, identifying patients earlier by selection criteria to spare OARs and further decrease the risk of complication will be beneficial to both patients and radiation departments. Previous studies selected patients by determining some criteria that would allow them to benefit from ART or replanning.4,15,16

In clinical practice, CT is the only imaging modality that can be used for treatment planning. Cone-beam CT (CBCT) integrated into linear accelerators cannot be used as a planning imaging modality because of its inferior image quality, poor electron density accuracy, scatter, and motion artifacts. However, CBCT scans possess the position and shape information of the target and organs at risk in real time. Daily or weekly on-board CBCT is used to assist patient setup. In addition, CBCT data can also potentially be used for dose reconstruction with the electron density calibrated. Yang et al. and Ding et al. studied the modified CBCT (mCBCT)-based dose reconstruction method and validated that it allowed for acceptable dosimetric evaluation.17,18 Furthermore, Hunter et al. already determined the PG dose-effect using weekly CBCT.14

In our previous study, we investigated dosimetric variations of the liver using deformable registration of planning CT (pCT) and CBCT and found that there was an increase in \( D_{\text{90}} \) and \( D_{\text{mean}} \) when compared with the planning dose.19 Additionally, a significant dosimetric difference between patients with and without radiation-induced liver disease (RILD) has been reported. Charlotte et al. stated in their review that only a few articles reported the clinical relevance of dosimetric changes in terms of complications of head and neck cancer patients.16 As for dosimetric variation, the delivered dose may not correspond to the planned dose. Several studies investigated PG dose variation and found great dosimetric changes.10,12,20 However, inaccuracies in the calculation of dosimetric change should not be ignored.

One of the reasons leading to the inaccuracies is that in most studies, treatment plans used to calculate dose distributions were constructed on CT acquired a few days before radiotherapy, such as repeated planning CT. Patients experience anatomical changes during the treatment course, and consequently, a plan based on pretreatment CT images cannot precisely reflect the actual dose distribution during fractionated IMRT. In that case, the correlation between clinical outcomes and dosimetric changes might not be accurate. Hence, a real-time imaging modality such as CBCT is a better choice for estimating the delivered dose and investigating the relevance of dosimetric changes and complications.

Xerostomia might not occur in salivary gland tumors because the administered radiation is usually restricted to the ipsilateral gland. However, for the nasopharynx, the parotid glands are usually affected by radiation, and severe and permanent xerostomia may result. In this study, 21 NPC patients were included to investigate the association between dosimetric factors and xerostomia. We hypothesize that the actual delivered dose based on CBCT correlates more closely with the development of xerostomia than the planning dose, and some dosimetric characteristics between patients with xerostomia and patients without xerostomia should be different. This study aims to validate the hypothesis by using the mCBCT approach.

2 | MATERIALS AND METHODS

2.A | Patients and tumors

This retrospective study involved 21 NPC patients. The patients’ selection criteria were as follows: (1) patients enrolled in this study were treated with IMRT at the Radiation Department of the Shandong Cancer Hospital and Institute between August 2010 and August 2015; (2) a positive biopsy for nasopharyngeal carcinoma was obtained for all of the patients, and (3) there were no recurrent
patients, nor had any undergone resection. Patients diagnosed with other malignances or treated with non-IMRT techniques were excluded. Among the 21 patients, eight developed xerostomia but the other 13 did not. All parotid glands of patients taken into consideration were outside the PTVs. Patient and tumor characteristics of the initial plan are shown in Table 1. The study was approved by the Shandong Cancer Hospital ethics committee. All patients provided written informed consent.

2.B | Treatment and planning

All patients underwent simulation on Philips CT Big Bore, immobilized in a supine position with a thermoplastic mask covering the head, neck, and shoulders. Intravenous contrast-enhanced CT using 3 mm slice thickness was carried out, ranging from the vertex to the manubria sternal joint for planning. These data were transferred to the treatment planning system (Pinnacle, version 9.2 to 9.8). Targets were delineated by clinicians with the assistance of a combination of CT and MRI. Magnetic resonance scans were obtained using the same position of simulation. The delineation of organs at risk was completed by physicians. All patients’ radiation doses were planned and delivered using inverse IMRT. The prescribed radiation dose was 70 Gy at 2 Gy per fraction delivered over 6–7 weeks (5 or 6 fractions a week). The objective parameter used in IMRT optimization for the PG was at least one PG $D_{\text{mean}} < 26$ Gy or $D_{50} < 30$ Gy. All patients underwent CBCT scans with linear accelerators (Varian Trilogy) once a week to correct setup errors before radiotherapy. CBCT scanning was performed with 2.5 mm slice thickness. These CBCT scans were noted as CBCT week 1, week 2, week 3, and so on. Patients included in the study received chemotherapy with cisplatin and/or tegafur.

2.C | Dose construction

A plan based on mCBCT was generated to calculate the delivered dose. First, weekly CBCT and pCT were registered using rigid registration, followed by deformable image registration (DIR) to obtain the correct Hounsfield unit (HU) value of CBCT. Then, beam configurations and dose constraints of the initial plan were reapplied to mCBCTs. The target volume and OAR delineations upon pCT were automatically propagated onto mCBCT using the deformation vector field resulting from the registration as described above. All automatically propagated delineations were checked by the same proficient physicist. Delineations would be revised if the mapping structures were not in accordance with the anatomy on the mCBCT unless the results satisfied the physicist. Last, the dose distribution was recalculated.

2.D | Gradient-based deformable image registration

3D/2D registration methods can be classified into three categories: extrinsic, intrinsic, or calibration-based. The intrinsic methods can be further divided into two main categories, feature- and intensity-based, and it is accepted that the latter has an important advantage over the former in that all available information can be utilized in the images. However, it is possible that registration would fail because of the inaccuracy of the CBCT intensity. Scatter is one of the main reasons for intensity inaccuracy. Many prior studies showed that the scattering of CBCT results in a low-frequency signal. That is to say, in the scatter artifact images, the shapes of almost all inner and outer object boundaries, such as boundaries between bone, fat, muscle, and air, can be perceived. Based on the characteristics of scatter, we proposed the gradient-based free-form deformation algorithm (GFFD).

The GFFD algorithm measures the similarity by using 3D gradient fields. The local polynomial approximation-intersection of confidence intervals algorithm is performed to accommodate the image sampling anisotropy. A “bi-directional” force along with an adaptive force strength adjustment is introduced to accelerate the effect of the convergence process. These strategies are expected to decrease the effects of the inconsistent intensities.

2.E | Dose calculation and accumulation

The planning dose was calculated at the time of treatment planning. The accumulated delivered dose was derived from the weekly CBCTs. Firstly, the weekly mCBCT was aligned and registered with

### Table 1 Characteristics of patients with xerostomia and patients without xerostomia.

| Characteristics | Patients with xerostomia ($n = 8$) | Patients without xerostomia ($n = 13$) |
|-----------------|----------------------------------|--------------------------------------|
| Gender          |                                  |                                      |
| Female          | 2                                | 3                                    |
| Male            | 6                                | 10                                   |
| Age (yr)        | Range 38–68                      | 16–51                                |
| ³KPS            | 80                               | 2                                    |
| 90              | 4                                | 9                                    |
| 100             | 0                                | 2                                    |
| TNM stage       |                                  |                                      |
| $T_1N_2M_0$     | 1                                | 1                                    |
| $T_2N_2M_0$     | 0                                | 2                                    |
| $T_2N_2M_x$     | 0                                | 1                                    |
| $T_2N_1M_x$     | 0                                | 1                                    |
| $T_2N_1M_0$     | 5                                | 4                                    |
| $T_3N_1M_1$     | 0                                | 1                                    |
| $T_3N_1M_0$     | 2                                | 0                                    |
| $T_4N_1M_0$     | 0                                | 1                                    |
| $T_4N_2M_0$     | 0                                | 2                                    |
| ⁴PG volume (cc) | Range 15.3–34.0                  | 8.9–28.9                             |

³KPS = Karnofsky performance status; ⁴PG = parotid gland.
the initial planning CT through rigid registration. Secondly, deformable registration was conducted to optimize the local regions. The corresponding registration fields, i.e., the inverse fields of GFFD, were used to propagate the daily doses. Each weekly mapped plan based on mCBCT was superimposed on the initial plan to estimate the cumulative delivered dose over the entire treatment course. The dose volume histogram was used to evaluate the $V_{20}$, $V_{30}$, $V_{40}$, $D_{50}$, and $D_{\text{mean}}$ of the PG. Figure 1 shows the derivation of the total planning dose and accumulated delivery dose. Figure 2 shows the forward and inverse registration steps.

2.F | Statistical analysis

The paired samples $t$-test was used to obtain the association between the planning dose and the actual delivered dose. The independent samples $t$-test was used to determine whether there is a statistically significant dose difference between patients with xerostomia and patients without xerostomia. All analyses were performed using IBM SPSS version 23.0 software. A $P$-value less than 0.05 was considered significant.

3 | RESULTS

3.A | Imaging and automatic propagation

Figure 3 shows the pCT and CBCT registration error of GFFD and Demons, respectively, for a head example. As can be seen from Figs. 3(c) and 3(d), the results of registration of GFFD are comparable to that of Demons, and they are even better than Demons in the regions marked by the red rectangle.

Figure 4 shows an example of the transverse plane, sagittal plane, and coronal plane, of planning CT, CBCT, and mCBCT respectively. As can be seen, the image quality of mCBCT contrasts well with CBCT, and it is comparable to that of pCT. There is less noise on the mCBCT as compared with CBCT. More importantly, the electron density of mCBCT is calibrated. Herein, accurate dose construction is allowed.

The inverse deformation field of registration mapped the contours on CBCT from pCT. Figure 5 illustrates the automatic propagation of the parotid gland of an NPC patient. The last row of Fig. 5 shows the deformed contours overlaid on the original CBCT images. As can be seen, the automatically generated contours on mCBCT match the structures on CBCT well, which allowed us to perform the delivered dose calculation.

3.B | Comparison of planning and delivery dose

A total of 42 parotid glands of 21 NPC patients were analyzed. Among the total 42 PGs, 34 PGs experienced an increase in cumulative delivered dose as compared with the planning dose, and eight PGs experienced a decrease. Nearly all patients had at least one gland that experienced an increase in the cumulative delivered dose compared to the planning dose. For the 42 PGs, the $D_{\text{mean}}$ of the cumulative dose increased by 9.5% as compared with that of planning dose. $D_{30}$, $V_{20}$, $V_{30}$, and $V_{40}$ increased by 8.4%, 11.3%, 28.6%, and 44.4% respectively. The association between planning doses and actual delivered doses was determined with the paired samples $t$-test (Table 2). From the results, we can see that the $V_{20}$ values between planning doses and delivered doses are correlated with each other. The same situation applies to $V_{30}$, $V_{40}$, $D_{50}$, and $D_{\text{mean}}$. Additionally, the $p$-values of the above dosimetric parameter differences between the planning doses and the delivered doses were all less than 0.05. The delivered doses dramatically increased compared with the planning doses.

3.C | Dosimetric parameters correlated with xerostomia

Of the 21 patients included in the study, eight developed xerostomia, while the rest of the patients did not. PG $V_{20}$, $V_{30}$, $V_{40}$, $D_{50}$, and $D_{\text{mean}}$
between patients with xerostomia and patients without xerostomia were compared. The dosimetric parameters of planning doses and delivery doses for patients with xerostomia and patients without xerostomia are presented in Tables 3 and 4. The results indicate that the PG $D_{\text{mean}}$ of planning doses for all patients exceeded the PG tolerance (26 Gy). The same situation applies to the PG $D_{\text{mean}}$ of delivered doses. Among the 21 patients, the PG $D_{\text{mean}}$ of planning doses and delivered doses were 30.6 Gy and 33.6 Gy, respectively, for patients with xerostomia, and 26.3 Gy and 28.0 Gy, respectively, for patients without xerostomia. PG $D_{\text{mean}}$ over parotid gland tolerance (26 Gy) was observed in 16 patients (16/21). The $D_{50}$ values of the planning doses and the delivered doses for all patients were below the PG tolerance (30 Gy). $V_{20}$, $V_{30}$, $V_{40}$, $D_{S50}$, and $D_{\text{mean}}$ of the planning doses for patients with xerostomia were all higher than those of patients without xerostomia. The same situation applied to $V_{20}$, $V_{30}$, $D_{S50}$, and $D_{\text{mean}}$ of the delivered doses. The $p$-values of $V_{20}$, $V_{30}$, $D_{S50}$, and $D_{\text{mean}}$ difference of the delivery dose between patients with xerostomia and patients without xerostomia are less than 0.05. However, for the planning doses, the significant dosimetric difference between the two groups is only embodied in $D_{50}$ and $D_{\text{mean}}$. Xerostomia is closely related to $V_{20}$, $V_{30}$, $D_{S50}$, and $D_{\text{mean}}$. The details of $V_{20}$, $V_{30}$, $D_{S50}$, and $D_{\text{mean}}$ for the two groups are shown in Fig. 6.
DISCUSSION

The algorithm of DIR has an impact on the results of this study because the HU value of mCBCT overridden by DIR would influence the accuracy of dose construction. Additionally, the DIR algorithm determines the accuracy of propagation of structural contours. We have researched the deformable registration algorithm over the last few years.24,25 We also researched automatic contouring based on segmentation for radiotherapy treatment planning.26–28 We found that intensity-based deformable registration algorithms are susceptible to distorting tissues because the presence of inconsistent intensities between CT and CBCT could cause significant registration errors. The DIR algorithm performed in this study was presented in our previous work, and was tested using phantom and clinical data, which demonstrated the significance of the registration method.23 We assessed the volume overlapping using the Dice Similarity coefficient (DSC) in that study. The DSC value between the contours propagated by the GFFD algorithm and the contours edited by the oncologist was 96% for the parotid gland.

Many studies have been devoted to investigating the side effects of radiotherapy in head and neck cancer. This is mainly because OARs and tumor target volumes of HNC are close to each other.16 The parotid gland is the most studied organ at risk in head and neck cancer. Most of the previous studies reported on anatomic and dosimetric changes of the PG. This trend of study can be explained by the fact that radiation dosimetric changes for PGs are associated with saliva reduction and xerostomia.29–31

**Fig. 4.** An example of the transverse plane, sagittal plane, and coronal plane of planning CT, CBCT, and mCBCT.

**Fig. 5.** One example of automatically propagated parotid gland contours from planning CT to mCBCT. The last row shows the deformed contours overlaid on the original CBCT images. The yellow and brown line on CT and CBCT images represents the contour of the right and left parotid gland respectively.
The differences between planning dose and delivered dose.

| Parameters | Planning | Delivery | Correlation | P value |
|------------|----------|----------|-------------|---------|
| $V_{20}$ (%) | $67.5 \pm 21.8$ | $73.2 \pm 21.6$ | $0.919$ | $<0.01$ |
| $V_{30}$ (%) | $31.7 \pm 14.0$ | $38.2 \pm 15.2$ | $0.747$ | $<0.01$ |
| $V_{40}$ (%) | $18.0 \pm 10.0$ | $22.5 \pm 10.9$ | $0.657$ | $<0.01$ |
| $V_{50}$ (%) | $23.8 \pm 5.2$ | $25.9 \pm 5.8$ | $0.789$ | $<0.01$ |
| $D_{mean}$ (Gy) | $27.9 \pm 5.4$ | $30.1 \pm 5.9$ | $0.809$ | $<0.01$ |

$V_{20}$ = the percentage of parotid gland volume that received 20 Gy in the total parotid gland.

$V_{30}$ = the percentage of parotid gland volume that received 20 Gy in the total parotid gland.

$V_{40}$ = dose to the 50% of the parotid gland.

| Parameter | $D_{mean}$ (Gy) |
|-----------|-----------------|
| Patients with xerostomia (n = 8) | 30 |
| Patients without xerostomia (n = 13) | 30 |
| $P$ value | $<0.01$ |

$V_{20}$ = the percentage of parotid gland volume that received 20 Gy in the total parotid gland.

$V_{30}$ = the percentage of parotid gland volume that received 20 Gy in the total parotid gland.

$V_{40}$ = dose to the 50% of the parotid gland.

CT scans for radiotherapy planning are acquired prior to treatment. Generally, patient posture and anatomic change occur during the course of radiotherapy. Hence, the dose actually delivered to the patient often differs from that of the initial plan. Charlotte et al. reviewed the literature published in the last decade and pointed out that, on average, the PG mean dose increase was 2.2 ± 2.6 Gy as compared to the dose calculated on the planning CT. They also emphasized that the largest PG dose increase found by Chen et al. and Cheng et al. was 10.4 Gy in the sixth week of radiotherapy, and the largest median dose was 7.8 Gy at the 25th fraction. These results are approximately consistent with ours. Our results showed that the average PG mean dose increase was 2.2 Gy ± 3.5 Gy, ranging from −6.7 to +8.6 Gy.

Radiologists usually concentrate more on the constraints of $D_{mean}$ and $D_{50}$ for the PG, but ignore $V_{20}$, $V_{30}$, and $V_{40}$, which could possibly lead to the development of xerostomia. The dose delivered to patients is usually different from that of planning because of positional error and anatomic variation. In this study, the dose delivered to patients dramatically increased as compared with the planning dose. Additionally, it was found that the $V_{20}$, $V_{30}$, $D_{50}$, and $D_{mean}$ of delivery doses for the PG between patients with xerostomia and patients without xerostomia were different. However, only $D_{20}$ and $D_{mean}$ for the PG were found to be different between the two groups while considering the planning doses. It is apparent that the difference of $V_{20}$ and $V_{30}$ between the two groups will not be detected if we only consider the dosimetric consequences based on initial plans. To some extent, it emphasizes the significance of CBCT-based image-guided radiotherapy for patient positioning and planning optimization.

A number of studies have described PG anatomic or dosimetric changes, but only a few studies have reported the clinical relevance of these factors with regard to complications. Several studies found that PG shrinkage could increase the incidence of complications, while Sanguineti et al. gave the opposite conclusion. Hunter et al. investigated the association of planning/delivery PG dose and salivary outcome, and he concluded that the associations of planning/delivery dose and salivary outcome were significant, but the relationship between dosimetric change and saliva flow was not strong. In the current study, we estimated the actual delivered dose by using weekly mCBCT and compared the dosimetric difference between patients with xerostomia and patients without xerostomia. Many studies reported factors that were correlated with dosimetric changes, such as weight loss, neck thickness, PG volume loss, and center of mass (COM) shift. It showed that PG volume loss significantly correlated with the dose deviation from the planning dose. Three large studies reported a significant correlation of PG dose with PG volume loss. However, on average, the relationship between these factors and dosimetric changes was still unclear.

Generally, PG volume will decrease after radiotherapy. Previous studies suggested that, on average, the PG volume reduction rate was 26 ± 11%. In our study, the PG volume reduction rate was 13.5% and 13.2%, respectively, for patients with xerostomia and patients without xerostomia (Table 5). Although there is little difference in the PG volume reduction rate between patients with xerostomia and patients without xerostomia, the dose deviations between the two groups greatly differ. More study is needed to explore this issue.

It is worth mentioning that although the $D_{mean}$ value of several patients without xerostomia was over the tolerance of 30 Gy, some were even larger than that of patients with xerostomia but they did not develop xerostomia (Fig. 7). Perhaps it is because xerostomia can be caused by several other factors such as physical status, age,
and oral nursing care. In addition, we found that elder patients were at high risk to suffer xerostomia. The average age of patients with xerostomia and patients without xerostomia is 53.2 and 33.4 yr old ($P = 0.02$) respectively.

Radiotherapy-induced xerostomia is the result of the deleterious effect of radiation, and it is necessary to monitor the dose delivered to the PGs. To some extent, severe and acute xerostomia can be combated and even be prevented if the dose to the PGs is limited or even decreased. On one hand, radiation protocols designed for the parotid gland and other salivary glands potentially can be further restricted. On the other hand, ART is considered to be an effective approach to correct anatomical variation and reduce the dose to OARs. Yet, it seems that not all patients are able to benefit from ART because it is challenged by time-consuming procedures and requires extra resources. Additionally, the selection criteria for identifying patients who may benefit from ART are ambiguous, which obstructs the implementation of ART. The replanning strategies, timing, and optimal number of treatments remain unclear so far. Many researchers are investigating these issues, and some have made new progress.$^{15,37}$ We firmly believe that it will lead us to new important discoveries if these studies can be performed using CBCT.

5 | CONCLUSION

Doses actually delivered to the parotid glands significantly increased compared with planning doses. Statistically significant differences in $V_{20}$, $V_{30}$, $D_{50}$, and $D_{mean}$ for parotid glands were found between patients with xerostomia and patients without xerostomia.

Table 5 The change of parotid gland volume for patients with xerostomia and patients without xerostomia.

| Time              | Patients with xerostomia ($n = 8$) | Patients without xerostomia ($n = 13$) |
|-------------------|------------------------------------|----------------------------------------|
| Pretreatment PG volume (cc) | $22.6 \pm 6.9$                     | $14.6 \pm 4.3$                         |
| Post-treatment PG volume (cc)  | $18.3 \pm 4.1$                     | $11.8 \pm 2.0$                         |
| Volumetric change (%)          | $13.5 \pm 23.5$                    | $13.2 \pm 24.4$                        |

Fig. 6. The reconstructed (a) $V_{20}$, (b) $V_{30}$, (c) $D_{50}$, and (d) $D_{mean}$, relative to the plan. Error bars indicate the standard deviation. Herein, no-xerostomia represents patients without xerostomia, and xerostomia represents patients with xerostomia.

Fig. 7. Delivered parotid gland $D_{mean}$ for 21 patients. Herein, P-L represents the left parotid gland, and R-L represents the right parotid gland. No. 1 to No. 8 patients developed xerostomia, and the remaining 13 did not. The dotted line along 30 Gy represents the tolerance of the parotid gland.
Xerostomia is closely related to $V_{20}$, $V_{30}$, $D_{50}$, and $D_{mean}$. Elder patients were at high risk for developing xerostomia. Efforts to further restrict the radiation dose to the parotid glands are expected to have an effect on decreasing the incidence of xerostomia, especially for older patients. Adaptive IMRT treatment planning using CBCT may be a useful way of treatment monitoring and optimization for head and neck cancer. The small number of patients limited our study. Independent and well-designed studies including more patients are needed for further exploration.

ACKNOWLEDGMENTS

The authors express great thanks to Dr. Lei Xing, Dr. Yong Yang, Dr. Ruijiang Li (Department of Radiation Oncology, Stanford University School of Medicine, Stanford, CA, USA) for their valuable suggestions and selfless assistance to this work. We also thank the supporting of Taishan scholar project of Shandong Province. This research was partially funded by the National Natural Science Foundation of China (NO. 61471226), Natural Science Foundation for Distinguished Young Scholars of Shandong Province (NO. JQ201516), Natural Science Foundation of Shandong Province (ZR2017BF005).

CONFLICTS OF INTEREST

The authors have no relevant conflicts of interest to disclose.

REFERENCES

1. Sciubba JJ, Goldenberg D. Oral complications of radiotherapy. Lancet Oncol. 2006;7:175–183.
2. Castelli J, Simon A, Louvel G, et al. Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia. Radiat Oncol. 2015;10:1.
3. Reali A, Anglesio SM, Mortellaro G, et al. Volumetric and positional changes of planning target volumes and organs at risk using computed tomography imaging during intensity-modulated radiation therapy for head-neck cancer: an “old” adaptive radiation therapy approach. Radiol Med. 2014;119:714–720.
4. Brown E, Owen R, Harden F, et al. Predicting the need for adaptive radiotherapy in head and neck cancer. Radiat Oncol. 2015;116:57–63.
5. Fang F-M, Chien C-Y, Tsai W-L, et al. Quality of life and survival outcome for patients with nasopharyngeal carcinoma receiving three-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy—a longitudinal study. Int J Radiat Oncol Biol Phys. 2008;72:356–364.
6. Pow EH, Kwong DL, McMillan AS, et al. Xerostomia and quality of life after intensity-modulated radiotherapy vs. conventional radiotherapy for early-stage nasopharyngeal carcinoma: initial report on a randomized controlled clinical trial. Int J Radiat Oncol Biol Phys. 2006;66:981–991.
7. Wu Q, Chi Y, Chen PY, Krauss DJ, Yan D, Martinez A. Adaptive replanning strategies accounting for shrinkage in head and neck IMRT. Int J Radiat Oncol Biol Phys. 2009;75:924–932.
8. Duma M, Kampfer S, Schuster T, Winkler C, Geinitz H. Adaptive radiotherapy for soft tissue changes during helical tomotherapy for head and neck cancer. Strahlenther Onkol. 2012;188:243–247.
9. Schwartz DL, Garden AS, Shah SJ, et al. Adaptive radiotherapy for head and neck cancer—dosimetric results from a prospective clinical trial. Radiother Oncol. 2013;106:80–84.
10. Chen C, Lin X, Pan J, Fei Z, Chen L, Bai P. Is it necessary to repeat CT imaging and replanning during the course of intensity-modulated radiation therapy for locoregionally advanced nasopharyngeal carcinoma? Jpn J Radiol. 2013;31:593–599.
11. Zhao L, Wan Q, Zhou Y, Deng X, Xie C, Wu S. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma. Radiother Oncol. 2011;98:23–27.
12. Nishi T, Nimishura Y, Shibata T, Tamura M, Nishigaito N, Okumura M. Volume and dosimetric changes and initial clinical experience of a two-step adaptive intensity modulated radiation therapy (IMRT) scheme for head and neck cancer. Radiother Oncol. 2013;106:85–89.
13. Yan D, Liang J. Expected treatment dose construction and adaptive inverse planning optimization: implementation for offline head and neck cancer adaptive radiotherapy. Med Phys. 2013;40:21719.
14. Hunter KU, Fernandes LL, Vineberg KA, et al. Parotid glands dose-effect relationships based on their actually delivered doses: implications for adaptive replanning in radiation therapy of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2013;87:676–682.
15. Brouwer CL, Steenbakkers RJ, van der Schaar A, et al. Selection of head and neck cancer patients for adaptive radiotherapy to decrease xerostomia. Radiother Oncol. 2016;120:36–40.
16. Brouwer CL, Steenbakkers RJ, Langendijk JA, Sijtsma NM. Identifying patients who may benefit from adaptive radiotherapy: does the literature on anatomic and dosimetric changes in head and neck organs at risk during radiotherapy provide information to help? Radiother Oncol. 2015;115:285–294.
17. Yang Y, Schreibmann E, Li T, Wang C, Xing L. Evaluation of on-board kV cone beam CT (CBCT)-based dose calculation. Phys Med Biol. 2007;52:685.
18. Ding GX, Duggan DM, Coffey CW, et al. A study on adaptive IMRT treatment planning using kV cone-beam CT. Radiother Oncol. 2007;85:116–125.
19. Huang P, Yu G, Chen J, et al. Investigation of dosimetric variations of liver radiotherapy using deformable registration of planning CT and cone-beam CT. Int J Radiat Oncol Biol Phys. 2012;104:84.
20. Nishi T, Nishimura Y, Shibata T, Tamura M, Nishigaito N, Okumura M. Volume and dosimetric changes and initial clinical experience of a two-step adaptive intensity modulated radiation therapy (IMRT) scheme for head and neck cancer. Radiother Oncol. 2013;106:85–89.
21. Brouwer CL, Steenbakkers RJ, Langendijk JA, Sijtsma NM. Identifying patients who may benefit from adaptive radiotherapy: does the literature on anatomic and dosimetric changes in head and neck organs at risk during radiotherapy provide information to help? Radiother Oncol. 2015;115:285–294.
22. Yang Y, Schreibmann E, Li T, Wang C, Xing L. Evaluation of on-board kV cone beam CT (CBCT)-based dose calculation. Phys Med Biol. 2007;52:685.
30. Beetz I, Schilstra C, van der Schaaf A, et al. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors. *Radiother Oncol*. 2012;105:101–106.

31. Deasy JO, Moiseenko V, Marks L, Chao KC, Nam J, Eisbruch A. Radiotherapy dose–volume effects on salivary gland function. *Int J Radiat Oncol Biol Phys*. 2010;76:S58–S63.

32. Marzi S, Pinnarò P, D’Alessio D, et al. Anatomical and dose changes of gross tumour volume and parotid glands for head and neck cancer patients during intensity-modulated radiotherapy: effect on the probability of xerostomia incidence. *Clin Oncol-UK*. 2012;24:e54–e62.

33. Belli ML, Scalco E, Sanguineti G, et al. Early changes of parotid density and volume predict modifications at the end of therapy and intensity of acute xerostomia. *Strahlenther Onkol*. 2014;190:1001–1007.

34. Sanguineti G, Ricchetti F, Thomas O, Wu B, McNutt T. Pattern and predictors of volumetric change of parotid glands during intensity modulated radiotherapy. *Br J Radiol*. 2013;86:20130363.

35. Broggi S, Fiorino C, Dell’Oca I, et al. A two-variable linear model of parotid shrinkage during IMRT for head and neck cancer. *Radiother Oncol*. 2010;94:206–212.

36. Wang ZH, Yan C, Zhang ZY, et al. Radiation-induced volume changes in parotid and submandibular glands in patients with head and neck cancer receiving postoperative radiotherapy: a longitudinal study. *Laryngoscope*. 2009;119:1966–1974.

37. Zhang P, Simon A, Rigaud B, et al. Optimal adaptive IMRT strategy to spare the parotid glands in oropharyngeal cancer. *Radiother Oncol*. 2016;120:41–47.